kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - other antineoplastic agents - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
faringovit pastilas ar ingveru un eikaliptu (2016.) pastila
meksmar natural & healthy products production and marketing co. ltd. - pastila
faringovit pastilas ar islandes ķērpi (2016.) pastila
meksmar natural & healthy products production and marketing co. ltd - pastila
fleximed® (2020.) tablete
pharmatech a.s. - tablete
vitamin k2 complex (2022.) kapsula, -
kapsula, -
omegamarine junior+ (2022.) kapsula
kapsula
dr. ohhira® standard 12 pienskĀbo baktĒriju celmu komplekss (2016.) kapsula
biobank co., ltd. - kapsula
valeron (paziņots 2011.) kapsula
medpro inc. sia - kapsula